(1 - 6 from 12
)
Gasping for dollars: Insurance companies take your breath away
www.acsh.org
[American Council on Science and Health] - ACSH's Dr. Josh Bloom doesn't like this trend one bit. “Instead of access to first-line drugs," he observes, "patients might have to first rely on second- or third-line therapies that may very well fail — and only then have a shot at the best drug.
Easing approvals for “breakthroughs” may have consequences
www.acsh.org
[American Council on Science and Health] - In response to this latest proposal, ACSH's Dr. Josh Bloom sees both pros and cons. “Moving efficacy trials to the post-marketing phase would, on the one hand, allow us to have new drugs faster,” he says. “But we will certainly see more problems with
Second chances for obesity drugs?
www.acsh.org
[American Council on Science and Health] - As ACSH's Dr. Josh Bloom points out, “The unusually high burden being placed on weight-loss drugs is no doubt a result of the Fen-Phen debacle of 1997, where the only really effective obesity drug was withdrawn after cases of heart valve damage were
Physicians: know thy patients' drugs
www.acsh.org
[American Council on Science and Health] - ACSH's Dr. Josh Bloom observes that this is not a new problem, nor is it restricted to cancer drugs. “There are dozens of drugs that are known to affect the function of the liver, where nutrients and chemicals are metabolised,” he explains.
sorted by relevance / date